Immunotherapy最新文献_第2页

Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours. 评估ci治疗的转移性实体瘤患者的口服营养支持和营养风险评分。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-20 DOI: 10.1080/1750743X.2026.2660558

Caner Acar, Gökhan Şahin, Haydar Çağatay Yüksel, Fatma Pinar Açar, Bilge Bayır, Irem Özdemir, Burçak Karaca, Erdem Göker

{"title":"Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.","authors":"Caner Acar, Gökhan Şahin, Haydar Çağatay Yüksel, Fatma Pinar Açar, Bilge Bayır, Irem Özdemir, Burçak Karaca, Erdem Göker","doi":"10.1080/1750743X.2026.2660558","DOIUrl":"https://doi.org/10.1080/1750743X.2026.2660558","url":null,"abstract":"Background: Malnutrition is common in metastatic cancer and may compromise outcomes. We evaluated whether oral nutritional supplementation (ONS) improves survival and compared the performance of nutritional risk scores in immune checkpoint inhibitor (ICI)-treated patients.Methods: We retrospectively analyzed 538 adults with metastatic solid tumors who initiated ICIs between 2015 and 2024. Baseline ONS use, clinicopathological variables, and laboratory parameters were recorded. Survival outcomes were assessed after 1:1 propensity score matching (PSM).Results: 246 matched patients were evaluated. ONS was not associated with better overall survival (OS: median 13.9 vs 11.0 months; p = 0.70) or progression-free survival (PFS: 3.4 vs 4.4 months; p = 0.11). Immune-related adverse events (irAEs) occurred in 40.2% of ONS users versus 34.0% of non-users (p = 0.469). The Geriatric Nutritional Risk Index (GNRI), Prognostic Nutritional Index (PNI), Controlling Nutritional Status (CONUT) score, and modified Glasgow Prognostic Score (mGPS) independently predicted OS and PFS (all p < 0.001), with PNI and mGPS showing the best discrimination. Subgroup analyses across nutritional scores revealed no survival benefit with ONS.Conclusions: ONS did not improve survival or rates of irAEs in metastatic patients receiving ICIs, whereas nutritional scores provided strong prognostic stratification. Prospective trials integrating longitudinal nutrition monitoring, immunonutrition, and multimodal cachexia therapy are warranted.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating pozelimab in the treatment of CHAPLE disease. 评价波兹利单抗治疗冠心病的疗效。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-24 DOI: 10.1080/1750743X.2026.2639273

Necmiye Keser Ozturk, Durmus Burak Demirkaya, Alper Bulutoglu, Asena Pınar Sefer, Ahmet Ozen

{"title":"Evaluating pozelimab in the treatment of CHAPLE disease.","authors":"Necmiye Keser Ozturk, Durmus Burak Demirkaya, Alper Bulutoglu, Asena Pınar Sefer, Ahmet Ozen","doi":"10.1080/1750743X.2026.2639273","DOIUrl":"10.1080/1750743X.2026.2639273","url":null,"abstract":"CHAPLE disease (Complement Hyperactivation, Angiopathic Thrombosis, and Protein-Losing Enteropathy [PLE]) is a rare, life-threatening disorder caused by biallelic mutations in the CD55 gene, which encodes decay-accelerating factor, a key regulator of the complement system. The disease typically manifests in early childhood with hypoalbuminemic edema, gastrointestinal symptoms, recurrent infections, and failure to thrive, alongside an elevated thrombotic risk due to complement-mediated endothelial injury and coagulation activation. Given these pathogenetic mechanisms, complement-targeted therapies have emerged as a rational approach to disease management. Eculizumab, a monoclonal antibody against complement component C5, initially demonstrated clinical benefit when administered on a compassionate-use basis. Building upon this success, pozelimab, a next-generation subcutaneous anti-C5 monoclonal antibody, was evaluated in CHAPLE patients and subsequently received U.S. FDA approval for this indication. Pozelimab effectively inhibits terminal complement activation, leading to sustained remission of PLE, obviating the need for albumin replacement, reducing hospitalization rates, improving symptom control and nutritional status, and ultimately enhancing overall quality of life. This review highlights the evolving role of pozelimab in CHAPLE disease by discussing its mechanistic basis, emerging clinical evidence, and implications for patient-centered care.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"75-87"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis. 一线免疫检查点抑制剂治疗复发/转移性头颈癌的疗效：一项系统综述和荟萃分析

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-04-14 DOI: 10.1080/1750743X.2026.2643939

Jiuli Zhou, Wenbo Tang, Liqiong Xue

{"title":"Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis.","authors":"Jiuli Zhou, Wenbo Tang, Liqiong Xue","doi":"10.1080/1750743X.2026.2643939","DOIUrl":"10.1080/1750743X.2026.2643939","url":null,"abstract":"Introduction: Immune checkpoint inhibitors (ICIs) have brought a paradigm shift in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), but their first-line efficacy remains inconsistent. This meta-analysis compared the efficacy of ICIs versus the EXTREME regimen in R/M HNSCC patients.Methods: Randomized controlled trials evaluating the efficacy of ICIs versus EXTREME in R/M HNSCC patients and reporting on programmed death-ligand 1 (PD-L1) expression, overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were included. Kaplan-Meier curves of OS and PFS were reconstructed; ORR was presented as odds ratios.Results: From an initial pool of 356 studies, three trials were included. In the total population, median OS was similar among ICI monotherapy (11.5 months), dual ICIs (12.5 months), and EXTREME (12.0 months). In the PD-L1 high expression population, ICI monotherapy and dual ICIs demonstrated a trend toward improved OS relative to EXTREME. EXTREME demonstrated better PFS and ORR than ICI monotherapy and dual ICIs in both the total and PD-L1 high expression populations.Conclusions: First-line ICI monotherapy and dual ICIs did not significantly improve OS, PFS, and ORR compared with EXTREME. However, a discernible trend suggested a potential survival benefit for ICIs in patients with high PD-L1 expression.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"131-138"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis. 派姆单抗联合化疗治疗晚期her2阴性胃癌或胃食管结癌：KEYNOTE-859 Q-TWiST分析

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-04-11 DOI: 10.1080/1750743X.2026.2647579

Lucjan Wyrwicz, Vasiliki Kalampoki, Adriana Valderrama, Kate Young

{"title":"Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis.","authors":"Lucjan Wyrwicz, Vasiliki Kalampoki, Adriana Valderrama, Kate Young","doi":"10.1080/1750743X.2026.2647579","DOIUrl":"10.1080/1750743X.2026.2647579","url":null,"abstract":"Aims: In KEYNOTE-859, pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with untreated locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, with manageable safety. This post hoc analysis assessed Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST).Participants and methods: Survival time was grouped into three health states: TOX (time with any grade ≥3 adverse event [AE] before disease progression), TWiST (time before PD or death without grade ≥3 AEs), and REL (time from PD to death). Q-TWiST was the sum of restricted mean survival time (RMST) in each state, weighted by utilities estimated using the EQ-5D-5L questionnaire. Relative gains in Q-TWiST ≥15% were considered \"clearly clinically important.\"Results: RMST was longer in TOX (2.30 months [95% CI, 1.28 to 3.44]) and TWiST (1.90 months [95% CI, -0.02 to 3.79]) and shorter in REL (-0.28 months [95% CI, -2.43 to 2.01]) with pembrolizumab plus chemotherapy versus chemotherapy at month 56, for a relative Q-TWiST gain of 20.90% (US algorithm) or 18.38% (standardized algorithm).Conclusions: A clearly clinically important Q-TWiST gain was observed with pembrolizumab plus chemotherapy versus chemotherapy in all participants.Clinical trials registration: www.ClinicalTrials.gov identifier is NCT03675737.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"161-167"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary: Headache and migraine experiences in people with primary immunodeficiency receiving GAMMAPLEX® 5% or 10% intravenous immunoglobulin therapy. 简明语言总结：接受GAMMAPLEX®5%或10%静脉注射免疫球蛋白治疗的原发性免疫缺陷患者的头痛和偏头痛经历。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-03 DOI: 10.1080/1750743X.2026.2633976

Bob Geng, Kim Clark

引用次数: 0

Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. 异基因造血干细胞移植后巨细胞病毒感染的免疫治疗进展。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-18 DOI: 10.1080/1750743X.2026.2644106

Yu Wang, Jiaying Wu, Xiaobing Huang, Yi Xiao

{"title":"Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation.","authors":"Yu Wang, Jiaying Wu, Xiaobing Huang, Yi Xiao","doi":"10.1080/1750743X.2026.2644106","DOIUrl":"10.1080/1750743X.2026.2644106","url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective curative therapy for hematologic malignancies. However, post-transplant cytomegalovirus (CMV) infection remains a common and serious complication, significantly impacting patient prognosis and survival. Currently available antiviral agents are limited by bone marrow suppression, nephrotoxicity, drug resistance, and high cost, highlighting the need for alternative therapeutic strategies. Advances in immunotherapy - including CMV-specific T cells (CMV-CTL), TCR-engineered T cells (CMV-TCR-T), and natural killer (NK) cell therapies - as well as antibody-based approaches and prophylactic vaccines, provide new avenues for CMV management. Future treatment paradigms may integrate antiviral therapy, immunotherapy, and vaccination to improve outcomes in patients experiencing CMV reactivation after transplantation. This review summarizes the current progress of immunotherapeutic strategies for CMV infection following allo-HSCT. Relevant literature was identified through PubMed, Embase, and Web of Science databases, covering the period from January 2000 to December 2025.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"117-129"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Financial barriers to immunotherapy: challenges and potential mitigation strategies: a review paper. 免疫疗法的财政障碍：挑战和潜在的缓解战略：综述文件。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-02 DOI: 10.1080/1750743X.2026.2639275

Hasan Numan, Arafat Tfayli

{"title":"Financial barriers to immunotherapy: challenges and potential mitigation strategies: a review paper.","authors":"Hasan Numan, Arafat Tfayli","doi":"10.1080/1750743X.2026.2639275","DOIUrl":"10.1080/1750743X.2026.2639275","url":null,"abstract":"Introduction: Since the ipilimumab's approval in 2011, immune checkpoint inhibitors (ICIs) have become an integral aspect of oncology practice, offering unparalleled survival benefits across various cancers. Financial toxicities associated with the high pricing of ICIs have put a major constraint on their incorporation into oncology practice. Financial barriers of ICIs are particularly more pronounced in low-middle-income countries (LMICs).Areas covered: This review aimed to summarize financial barriers associated with the integration of immunotherapy into oncology practice, including dosing, pharmacoeconomic insufficiencies, flat-dosing overuse, out-of-pocket expenditures in LMICs, and structural barriers to access, such as limited reimbursement, and lack of biosimilars. We integrated evidence on dose optimization, de-escalation strategies, and health-care policies that can mitigate costs. Furthermore, we outlined the under-representation of LMICs in trials and the limited evidence on low-dose strategies from prospective data.Literature search: We performed a comprehensive literature review on PubMed and Google Scholar for English-language studies published between 2014 and 2025 using terms related to \"immunotherapy,\" \"financial toxicity,\" \"dose optimization,\" and 'low- and middle-income countries.\"Commentary: Dose-optimization strategies can reduce costs without compromising clinical efficacy, especially where financial barriers threaten continuity of care. Priorities include, prospective trials validating reduced dosing and international partnerships to integrate LMICs into research.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"89-97"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers. 免疫检查点抑制剂在泌尿系统癌症中成功的MicroRNA预后标志物。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-10 DOI: 10.1080/1750743X.2026.2640756

Panagiotis J Vlachostergios, Konstatinos Evmorfopoulos, Konstantinos Marsitopoulos, Ioannis Tamposis, Maria Samara, Eleni Thodou, Panagiotis Sarantis, Dimitrios Matthaios, Michalis V Karamouzis, Vassilios Tzortzis, Antonis Giakountis

{"title":"MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers.","authors":"Panagiotis J Vlachostergios, Konstatinos Evmorfopoulos, Konstantinos Marsitopoulos, Ioannis Tamposis, Maria Samara, Eleni Thodou, Panagiotis Sarantis, Dimitrios Matthaios, Michalis V Karamouzis, Vassilios Tzortzis, Antonis Giakountis","doi":"10.1080/1750743X.2026.2640756","DOIUrl":"10.1080/1750743X.2026.2640756","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have significantly transformed the treatment landscape of urologic malignancies, including bladder cancer, renal cell carcinoma (RCC), and prostate cancer. Despite impressive clinical responses in subsets of patients, the heterogeneity of response highlights the urgent need for robust prognostic biomarkers. MicroRNAs (miRNAs) - small non-coding RNAs that regulate gene expression post-transcriptionally - have emerged as pivotal players in tumor immune regulation and cancer progression. This review synthesizes current evidence on miRNA prognostic markers predictive of ICI success in urologic cancers, emphasizing their biological functions, clinical utility, and therapeutic implications. We discuss miRNA signatures with prognostic value, their mechanisms modulating immune checkpoints, and prospects for integrating miRNA profiling into personalized immunotherapy strategies. This work provides the first cancer-type - stratified synthesis linking mechanistic data, circulating biomarkers, and therapeutic modulation on miRNAs and ICIs in urologic cancers.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"99-116"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13094240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report. tarlatamab（一种dll3靶向双特异性t细胞结合剂）治疗晚期食管小细胞神经内分泌癌的疗效和安全性：1例报告

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-03-28 DOI: 10.1080/1750743X.2026.2652156

Bahadır Köylü, Cevat İlteriş Kıkılı, Fatih Kemik, Nazan Demir, Orhun Çığ Taşkın, Afak Durur Karakaya, Shaheenah Dawood, Fatih Selçukbiricik

{"title":"Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report.","authors":"Bahadır Köylü, Cevat İlteriş Kıkılı, Fatih Kemik, Nazan Demir, Orhun Çığ Taşkın, Afak Durur Karakaya, Shaheenah Dawood, Fatih Selçukbiricik","doi":"10.1080/1750743X.2026.2652156","DOIUrl":"10.1080/1750743X.2026.2652156","url":null,"abstract":"The limited efficacy of current therapeutic options highlights a clear unmet need in patients with digestive neuroendocrine carcinoma. Tarlatamab is a bispecific T-cell engager targeting CD3 on T cells and delta-like ligand 3 on tumor cells. Since delta-like ligand 3 is highly expressed in digestive neuroendocrine carcinomas, tarlatamab might be a potential treatment option in this setting. However, the efficacy of tarlatamab in patients with digestive neuroendocrine carcinoma remains unknown. Herein, we report a case of metastatic esophageal neuroendocrine carcinoma that achieved a complete radiologic response following treatment with tarlatamab. A 47-year-old woman presented with progressive dysphagia and was diagnosed with esophageal small-cell neuroendocrine carcinoma with mediastinal lymph node metastases. She received first-line chemoimmunotherapy and radiotherapy to the primary tumor and mediastinal lymph nodes. Following three months of maintenance therapy with atezolizumab, new metastatic lesions in the liver and brain developed. Second-line treatment with tarlatamab was initiated. Tarlatamab induced complete resolution of the metastatic lesions in the liver and brain, without adverse events attributable to tarlatamab. This case underscores the potential value of delta-like ligand 3-targeted therapy with tarlatamab in metastatic digestive neuroendocrine carcinoma, a rare and highly aggressive malignancy with few effective treatment options.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"181-185"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13154954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives. 支气管镜冷冻免疫治疗在非小细胞肺癌中的作用：目前的证据和未来的展望。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-04-16 DOI: 10.1080/1750743X.2026.2651072

Phillip N Perez, Illaa Smesseim, Daniel H Sterman

{"title":"The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives.","authors":"Phillip N Perez, Illaa Smesseim, Daniel H Sterman","doi":"10.1080/1750743X.2026.2651072","DOIUrl":"10.1080/1750743X.2026.2651072","url":null,"abstract":"Lung cancer is the leading cause of cancer deaths, and despite therapeutic advances, recurrence and resistance persist. Local tumor ablation can function as an in situ vaccine, but thermal techniques may disrupt antigen and extracellular matrix integrity, potentially limiting immunogenicity, whereas cryoablation has been shown to preserve tumor antigens and matrix architecture while inducing immunogenic cell death. Bronchoscopic cryoimmunotherapy (BCI) aims to prime antitumor immunity rather than achieve complete tumor eradication. We review preclinical and clinical studies evaluating cryoablation and BCI in non-small cell lung cancer (NSCLC), focusing on immune mechanisms, delivery approaches, and combination with systemic therapies, particularly immune checkpoint inhibitors (ICIs). Preclinical models demonstrate that cryoablation releases danger signals and intact tumor antigens, drives dendritic cell maturation, expands effector CD8+ T cells, and activates STING-dependent type I interferon pathways. Early-phase human studies of BCI monotherapy show systemic immune stimulation, including reductions in the derived neutrophil-to-lymphocyte ratio and expansion of CD8+ effector memory populations. Combination cryoablation-ICI regimens have revealed improved response rates in some cohorts, although clinical outcomes have been limited by small, heterogeneous, and non-randomized studies. BCI is a mechanistically compelling, minimally invasive therapy, but its clinical benefit remains unproven and warrants rigorous randomized evaluation.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"237-247"},"PeriodicalIF":2.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13155028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0